Drugs tested in low- and middle-income countries are often not available for use in these countries even after a few years.
10 May, 2021 | 00:54h | UTC
Commentary on Twitter
Sharing benefits and burdens of clinical research? Or not…
Of 70 countries enrolling pts. for new-drug trials, 7% got market access to the drugs they helped test <1 year after FDA approval, 31% did so at 5 years. Lowest access in Africa & Middle East?https://t.co/p2uCP43hOG pic.twitter.com/cqsucO1kxP
— Søren M Bentzen (@SorenBentzen) May 6, 2021